Amylin Analogue
Long-Acting Amylin Analogue
Best For
Metabolic protocols seeking GLP-1-independent pathways, combination weight management strategies
Amylin
Receptor pathway activated
1x/wk
Dosing frequency (long-acting analogue)
Additive
Effect when combined with GLP-1 agonists
How It Works
This long-acting amylin analogue is an acylated analogue of the pancreatic hormone amylin, engineered for once-weekly dosing. It activates amylin receptors in the area postrema and nucleus of the solitary tract, inducing satiety signals that reduce caloric intake independently of the GLP-1 pathway. It also slows gastric emptying, contributing to prolonged post-meal fullness. Research suggests its mechanism is complementary to GLP-1 receptor agonists, which is why combination protocols (e.g., amylin + GLP-1 combinations) have shown additive weight reduction in clinical trials.
Key Research Areas
Satiety Signaling
Activates amylin receptors in the area postrema to reduce hunger independently of GLP-1
Gastric Regulation
Slows gastric emptying for sustained post-meal satisfaction
GLP-1 Synergy
Complementary mechanism produces additive effects when combined with incretin therapies
Weekly Dosing
Acylated design enables long-acting, once-weekly administration
Research Highlights
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Formulation Notes
Common concentrations referenced in published clinical studies:
[CGL5]5mg[CGL10]10mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
First-Generation GLP-1
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgAmylin + GLP-1 Combination
Amylin + GLP-1 Dual Agonist
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Reference Codes
[CS10]10mg (Amylin 5mg + GLP-1 5mg)Second-Generation GLP-1
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgEvidence reviewed: March 2026